Name | Number of supported studies | Average coverage | |
---|---|---|---|
type B pancreatic cell | 4 studies | 75% ± 14% |
Insufficient scRNA-seq data for expression of IAPP at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 98% | 2472.05 | 320 / 328 | 63% | 55.83 | 113 / 178 |
liver | 81% | 44.73 | 182 / 226 | 4% | 0.69 | 17 / 406 |
prostate | 0% | 0 | 0 / 245 | 9% | 0.81 | 47 / 502 |
kidney | 3% | 0.46 | 3 / 89 | 0% | 0.00 | 2 / 901 |
thymus | 2% | 0.44 | 14 / 653 | 1% | 0.02 | 6 / 605 |
brain | 3% | 0.73 | 77 / 2642 | 0% | 0.00 | 1 / 705 |
intestine | 1% | 0.12 | 6 / 966 | 2% | 1.94 | 12 / 527 |
esophagus | 1% | 0.10 | 11 / 1445 | 2% | 0.02 | 3 / 183 |
adrenal gland | 0% | 0 | 0 / 258 | 2% | 0.05 | 4 / 230 |
stomach | 1% | 0.09 | 2 / 359 | 1% | 0.03 | 3 / 286 |
lung | 0% | 0.06 | 1 / 578 | 1% | 0.03 | 16 / 1155 |
breast | 1% | 0.43 | 4 / 459 | 1% | 0.57 | 7 / 1118 |
skin | 1% | 0.23 | 18 / 1809 | 0% | 0.01 | 2 / 472 |
ovary | 0% | 0 | 0 / 180 | 1% | 0.02 | 5 / 430 |
adipose | 1% | 0.59 | 13 / 1204 | 0% | 0 | 0 / 0 |
heart | 1% | 0.12 | 7 / 861 | 0% | 0 | 0 / 0 |
uterus | 0% | 0 | 0 / 170 | 0% | 0.01 | 2 / 459 |
spleen | 0% | 0.11 | 1 / 241 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.02 | 2 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0.09 | 3 / 1335 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 0% | 0.00 | 1 / 504 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019233 | Biological process | sensory perception of pain |
GO_0050850 | Biological process | positive regulation of calcium-mediated signaling |
GO_0030316 | Biological process | osteoclast differentiation |
GO_0045779 | Biological process | negative regulation of bone resorption |
GO_0007165 | Biological process | signal transduction |
GO_0031333 | Biological process | negative regulation of protein-containing complex assembly |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0007267 | Biological process | cell-cell signaling |
GO_0097647 | Biological process | amylin receptor signaling pathway |
GO_0010739 | Biological process | positive regulation of protein kinase A signaling |
GO_1905907 | Biological process | negative regulation of amyloid fibril formation |
GO_0042755 | Biological process | eating behavior |
GO_0045453 | Biological process | bone resorption |
GO_0006915 | Biological process | apoptotic process |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0045671 | Biological process | negative regulation of osteoclast differentiation |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0008289 | Molecular function | lipid binding |
GO_0048018 | Molecular function | receptor ligand activity |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0005179 | Molecular function | hormone activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IAPP |
Protein name | Islet amyloid polypeptide (Amylin) (Diabetes-associated peptide) (DAP) (Insulinoma amyloid peptide) Islet amyloid polypeptide Islet amyloid polypeptide (Amylin) |
Synonyms | |
Description | FUNCTION: Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism. FUNCTION: Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism. . FUNCTION: Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism. . |
Accessions | ENST00000535428.1 ENST00000240652.8 F5H0S1 P10997 H0YF85 ENST00000537593.1 ENST00000542023.1 ENST00000539393.5 F5H1F0 |